DoW Kidney Cancer, Academy of Kidney Cancer Investigators Early-Career Scholar Award

The Academy of Kidney Cancer Investigators – Early-Career Scholar Award is administered by the Defense Health Agency through the Congressionally Directed Medical Research Programs as part of the Kidney Cancer Research Program. Established to advance innovative and impactful kidney cancer research, the program also serves as a structured career development platform for early-career investigators. It operates through a virtual academy model that integrates mentorship, collaboration, and professional development, with the broader mission of building a sustained pipeline of researchers capable of advancing treatment and improving outcomes for individuals affected by kidney cancer. The primary purpose of this funding opportunity is to support early-career scholars in conducting high-quality kidney cancer research while simultaneously fostering their development into independent investigators. The program emphasizes both scientific merit and career trajectory, requiring applicants to demonstrate strong potential for leadership in the field. Scholars are paired with experienced mentors and participate in a collaborative network that includes leadership teams and patient advocacy groups. Research projects may span basic, translational, or clinical domains but must align with defined focus areas such as understanding disease biology, developing therapeutic strategies, improving patient care, or addressing disparities in outcomes. Funding is substantial, with awards capped at 1.2 million dollars over a maximum performance period of four years. The program anticipates awarding approximately two grants from a total funding pool of about 2.4 million dollars. Funds may be used for research activities, personnel salaries, travel for required academy events, and collaboration-related expenses. However, certain restrictions apply, including the prohibition of clinical trial costs and tuition expenses. Awardees are required to participate in academy activities such as workshops and webinars, which are integral to the program’s collaborative and developmental framework. Eligibility is broad at the organizational level, encompassing domestic and international entities across public, private, nonprofit, and for-profit sectors. However, strict criteria apply to the principal investigator, who must qualify as an early-career scholar within seven years of completing their terminal training and must not be in a postdoctoral position at the time of application submission. Applicants must also demonstrate institutional support, including protected research time, and must not hold conflicting career development awards. A designated mentor with a strong record in kidney cancer research is required, and additional mentorship may be necessary depending on institutional arrangements. The application process follows a two-step submission structure. Applicants must first submit a letter of intent through the Electronic Biomedical Research Application Portal, followed by a full application submitted via either Grants.gov or eBRAP depending on organizational type. The full application includes multiple required components such as a project narrative, technical and lay abstracts, a career development plan, and letters of support. The process also involves compliance checks and a two-tier review system consisting of peer review and programmatic review, evaluating both scientific merit and alignment with program priorities. Key deadlines for the current cycle include a pre-application submission deadline in mid-September 2026 and a full application deadline later that month. Peer review is scheduled for December 2026, followed by programmatic review in March 2027, with funding decisions anticipated thereafter. Awards are expected to be finalized by September 2027. The program does not require cost sharing and provides extensive guidance and support resources to applicants, including help desks and instructional materials. Overall, this funding opportunity represents a comprehensive investment in both scientific research and workforce development within the kidney cancer field. By combining significant financial support with structured mentorship and collaborative engagement, the program aims to accelerate discoveries while cultivating the next generation of leaders in cancer research.

Strong emphasis on career development plan and mentor quality; ensure alignment with kidney cancer focus areas; demonstrate feasibility with preliminary data; clearly articulate independence trajectory